Previous 10 | Next 10 |
home / stock / amgn / amgn articles
Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.01% on an annualized basis producing an average annual return of 8.86%....
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDA...
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.07% on an annualized basis producing an average annual return of 9.12%....
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial o...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...
Thursday, the FDA approved Amgen Inc’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for the treatment of adult patients with exte...
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage company focused on developing novel therapeutics for metabolic and endocrine disorders, has be...
News, Short Squeeze, Breakout and More Instantly...
2024-06-29 08:45:00 ET If there is one thing income investors like more than regular dividend payouts, it's regular and growing dividend payouts. Not every corporation can offer that, of course. Some will eventually suspend their dividend programs or, at the very least, decrease their p...
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...
2024-06-20 08:15:00 ET Amgen (NASDAQ: AMGN) is a top drugmaker whose shares have risen by more than 70% in five years, which is a bit shy of the S&P 500 's 90% gain over that stretch. With some promising products in its pipeline, the future does looks encouraging. However, s...